Barely Significant
← all excerpts

Improving the tolerability of osimertinib by identifying its toxic limit.

Ther Adv Med Oncol · 2022 · PMC9168866 · PMID 35677320

Europe PMCDOI
1
hedged sentence
0.1000
closest p · 2.0× alpha
0.1000
boldest claim

The sentences

a trend toward significancep = 0.10so close (0.05 < p ≤ 0.1)
After correction for CRP, alkaline phosphatase, hemoglobin, primary EGFR mutation, and WHO performance status >1, only a trend toward significance remained for osimertinib exposure (HR 0.95, 95% CI 0.89–1.00; p = 0.10).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.